{
  "id": 16424598,
  "title": "New blood test could help flag risk of condition that leads to liver failure, cancer",
  "url": "https://urgent.news/2026/10/25/new-blood-test-could-help-flag-risk-of-condition-that-leads-to-liver",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-25T04:00:00.000Z",
  "source": {
    "name": "Straits Times",
    "slug": "straits-times",
    "url": "https://www.straitstimes.com/singapore/health/new-blood-test-could-help-prevent-condition-that-leads-to-liver-failure-cancer"
  },
  "original_language": "en",
  "account": "A new blood test called CIRRHOClear, developed by Singapore-based biotech firm Mirxes and the National Cancer Centre Singapore (NCCS), can identify the risk of liver cirrhosis before symptoms develop, potentially minimizing the risk of liver failure and liver cancer. The non-invasive test measures specific microRNA biomarkers in a standard blood sample, providing a high, intermediate or low risk classification for the condition. In clinical validation studies, CIRRHOClear accurately determined liver cirrhosis risk in 89% of cases and correctly identified those without the condition 95% of the time. Early detection through CIRRHOClear could allow doctors to manage the condition better, potentially slowing its progression and mitigating symptoms. Liver cirrhosis, caused by chronic liver damage from conditions like fatty liver disease, chronic hepatitis or alcohol-related liver disease, is a serious medical situation that can lead to liver failure and hepatocellular carcinoma, the most common form of liver cancer. Currently, detecting liver cirrhosis in its early stages is challenging, with routine blood tests and ultrasound lacking sensitivity. CIRRHOClear aims to address this issue by providing a practical risk-stratification tool for primary care providers, transforming liver care from reactive treatment to proactive prevention. The test, which involves drawing a small amount of blood, will be available at clinics and screening centers starting October 16, 2023, with plans to introduce the product in other countries.",
  "summary": "Globally, about 1.43 million deaths were linked to liver cirrhosis in 2021.",
  "key_points": [
    "CIRRHOClear blood test identifies liver cirrhosis risk before symptoms appear",
    "Non-invasive test measures microRNA biomarkers in standard blood sample",
    "89% accuracy in determining cirrhosis risk, 95% in correctly identifying non-cirrhosis cases"
  ],
  "editors_take": "Shifting liver care from reactive treatment to proactive prevention allows primary care providers to intervene before symptoms emerge and mitigate the risk of life-threatening complications like liver failure.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}